A Study of IMR-687 in Subjects With Sickle Cell Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sickle Cell Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Masking Description: Double-BlindPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
A phase 2b, randomized, double-blind, placebo-controlled, multicenter study of subjects with sickle cell disease (SCD; homozygous sickle hemoglobin [HbSS], sickle-?0 [HbSB0] thalassemia, or sickle-?+ [HbSB+] thalassemia) to evaluate the safety and efficacy of the phosphodiesterase type 9 (PDE9) inhi...
A phase 2b, randomized, double-blind, placebo-controlled, multicenter study of subjects with sickle cell disease (SCD; homozygous sickle hemoglobin [HbSS], sickle-?0 [HbSB0] thalassemia, or sickle-?+ [HbSB+] thalassemia) to evaluate the safety and efficacy of the phosphodiesterase type 9 (PDE9) inhibitor, IMR-687, administered once daily (qd) for 52 weeks.
Tracking Information
- NCT #
- NCT04474314
- Collaborators
- Not Provided
- Investigators
- Study Director: Kenneth Attie, MD Imara, Inc.
Get Well Soon